Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:18 2024-05-24 am EDT			5-day change	1st Jan Change
0.044 ^AUD	0.00%		+2.33%	-29.03%

Mar. 25	Transcript : Prescient Therapeutics Limited - Special Call
Feb. 23	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Prescient Therapeutics Announces Appointment of Phillip Darcy to Scientific Advisory Board

August 06, 2020 at 07:10 pm EDT

Prescient Therapeutics announced the appointment of Professor Phillip Darcy to its Scientific Advisory Board. Professor Darcy is currently National Health and Medical Research Council senior research fellow and group leader of cancer immunotherapy at the Peter MacCallum Cancer Centre in Melbourne.

Latest news about Prescient Therapeutics Limited

Transcript : Prescient Therapeutics Limited - Special Call	Mar. 24
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	Nov. 27	MT
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-24	CI
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	23-05-14	CI
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	23-03-15	CI
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	23-03-08	MT
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	23-03-08	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Transcript : Prescient Therapeutics Limited - Shareholder/Analyst Call	22-11-28
Prescient Therapeutics Sees Positive Results in PTX-100 Study	22-10-26	MT
Prescient Therapeutics Limited Announces PTX-100 Trial Update	22-10-24	CI
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	22-09-22	MT
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	22-09-22	CI
Transcript : Prescient Therapeutics Limited - Special Call	22-09-08
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	22-09-06	MT
Transcript : Prescient Therapeutics Limited - Special Call	22-09-06
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	22-09-06	CI
Prescient Therapeutics Launches $6 Million Share Purchase Plan	22-08-24	MT
Transcript : Prescient Therapeutics Limited - Special Call	22-08-22
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	22-08-17	CI
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead	22-08-16	MT
Prescient Therapeutics Secures Orphan Drug Designation in US for Lymphoma Drug; Shares Rally 19%	22-07-14	MT
Prescient Therapeutics Secures US Patent for OmniCAR Platform; Shares Rise 6%	22-07-04	MT

Chart Prescient Therapeutics Limited

Duration

Period

More charts

Company Profile

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRESCIENT THERAPEUTICS LIMITED	-29.03%	23.5M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research